Document is current
Any future updates will be listed below
-
Authors
Chouaid, Christos https://orcid.org/0000-0002-4290-5524
Bosquet, Lise https://orcid.org/0000-0001-5100-9425
Girard, Nicolas https://orcid.org/0000-0001-9909-2299
Kron, Anna https://orcid.org/0000-0002-3047-6486
Scheffler, Matthias https://orcid.org/0000-0002-9031-1368
Griesinger, Frank https://orcid.org/0000-0002-6822-5498
Sebastian, Martin https://orcid.org/0000-0002-0404-7741
Trigo, Jose https://orcid.org/0000-0002-4489-2683
Viteri, Santiago https://orcid.org/0000-0001-8877-4649
Knott, Craig https://orcid.org/0000-0002-8593-6216
Rodrigues, Bernardo
Rahhali, Nora https://orcid.org/0000-0002-7989-6035
Cabrieto, Jedelyn https://orcid.org/0000-0001-6413-2000
Diels, Joris https://orcid.org/0000-0002-9456-9120
Perualila, Nolen J.
Schioppa, Claudio A. https://orcid.org/0000-0002-4148-4676
Sermon, Jan
Toueg, Raphael
Erdmann, Nicole
Mielke, Janka
Nematian-Samani, Mehregan
Martin-Fernandez, Cristina
Pfaira, Innocent
Li, Tracy
Mahadevia, Parthiv
Wolf, Jürgen https://orcid.org/0000-0002-3869-4736
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct02609776 at ClinicalTrials.govDocuments that mention this clinical trial
An Adjusted Treatment Comparison Comparing Amivantamab Versus Real-World Clinical Practice in Europe and the United States for Patients with Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Exon 20 Insertion Mutations
https://doi.org/10.1007/s12325-022-02408-7
Amivantamab and lazertinib in treatment-naïve <i>EGFR-</i>mutated advanced non–small-cell lung cancer (NSCLC): Long-term follow-up and ctDNA results from CHRYSALIS.
https://doi.org/10.1200/jco.2023.41.16_suppl.9134
Risk factors for venous thromboembolism (VTE) among patients with <i>EGFR</i>-mutated advanced non-small cell lung cancer (NSCLC) receiving amivantamab plus lazertinib versus either agent alone.
https://doi.org/10.1200/jco.2023.41.16_suppl.9137
-
Funding
Funding for this research was provided by:
Janssen Pharmaceutica NV
- License Information
-
More Information
Article History
Received: 5 October 2022
Accepted: 12 December 2022
First Online: 18 January 2023
